Pathology Oncology Research

, Volume 9, Issue 2, pp 100–103 | Cite as

Is Nothingham Prognostic Index correlated with apoptosis and P53 expression in infiltrating ductal carcinoma of the breast?

  • Esin Cengiz-Boduroglu
  • Çigdem Irkkan
  • Gülay Bilir


The role of p53 as a prognostic factor is not clear. P53 named as “guardian of the genome” plays an important role in many intracellular regulatory systems, one of which is apoptosis, having an impact on tumor kinetics. A retrospective study was undertaken to assess the relationship of the Nothingham Prognostic Index (NPI) to p53 expression and apoptotic cell counts. To conduct the study, 160 successive cases of infiltrating ductal carcinoma of the breast were included. P53 was assessed on AP-AAP stained sections. Apoptotic cell counting (ACC) was done on the HE stained routine sections in 10 HPFs. Clinical data were derived from the hospital files. Apoptotic cell counts were higher in the p53 positive group but the difference was not significant (p=0.079). P53 positivity was found to be related to the disease-free survival (DFS) (p=0.008). NPI was significantly higher in apoptotic cell containing group (p=0.006). There was a positive linear correlation between ACC and NPI scores (p=0.004). This correlation was not present between apoptosis and disease free survival. P53 expression was found to be related with DFS but not with the NPI which is a score composed of the best prognostic indicators known today. In contrast to this, ACC was found to be closely and linearly associated to the known prognostic factors. This may suggest that the apoptotic cell counts done on routine sections may be used as a part of prognosis assessment in infiltrating ductal carcinoma.


p53 apoptosis disease free survival prognostic index 



Nothingham Prognostic Index


Alkaline Phosphatase - Anti Alkaline Phosphatase


High Power Field




Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Askmalm-Stenmark M, Stal O, Sullivan S, Ferraud L, et al.: Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur J Cancer 30A:175–180, 1994CrossRefGoogle Scholar
  2. 2.
    Baak JP, Dop H, Kurver PHJ: The value of morphometry to classic prognosticators in breast cancer. Cancer 56:374–382, 1985PubMedCrossRefGoogle Scholar
  3. 3.
    Barnes DM, Dublin AE, Fisher CJ, et al: Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis? Hum Pathol 24:469–476, 1993PubMedCrossRefGoogle Scholar
  4. 4.
    Cummings MC, Winterford CM, Walker NI: Apoptosis. Am J Surg Pathol 21:88–101, 1997PubMedCrossRefGoogle Scholar
  5. 5.
    Elston CW Ellis IO: Pathological prognostic factors in breast cancer. Histopathology 19:403–410, 1991PubMedCrossRefGoogle Scholar
  6. 6.
    Gonzales-Campora R, Galera Ruiz MR, Vasquez RF, et al.: Apoptosis in breast carcinoma. Pathol Res Pract 196: 167–174, 2000Google Scholar
  7. 7.
    Haybittle JL, Blarney RW Elston CW: A prognostic index in primary breast cancer. Br J Cancer 45:361–366, 1982PubMedGoogle Scholar
  8. 8.
    Kovach JS, Hartmann A, Blaszyk H: Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 93:1093–1096, 1996PubMedCrossRefGoogle Scholar
  9. 9.
    Lane DP: p53, guardian of the genome. Nature 358:15–16, 1992PubMedCrossRefGoogle Scholar
  10. 10.
    Lipponen P, Aaltomaa S, Kosma VM, Syrjanen K: Apoptosis in breast cancer as related to histopathologic characteristics and prognosis. Eur J Cancer 30A:2068–2073, 1994PubMedCrossRefGoogle Scholar
  11. 11.
    Moll UM, Ostermeyer AG, Ahomadegbe JC: P53 mediated tumor cell response to chemotherapeutic DNA damage: a preliminary study in matched pairs of breast cancer biopsies. Hum Pathol 26:1293–1301, 1995PubMedCrossRefGoogle Scholar
  12. 12.
    O’Malley FP, Saad Z, Kerkvliet N, Doig G, et al.: The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erbB2 in lymph node negative breast cancer. Hum Pathol 27:955–963, 1996PubMedCrossRefGoogle Scholar
  13. 13.
    Ozbun MA, Butel JS: Tumor suppressor p53 mutations and breast cancer: critical analysis. Adv Cancer Res 66:71–7, 1995PubMedCrossRefGoogle Scholar
  14. 14.
    Sher CJ: Cancer cell cycles. Science 274:1672–1677, 1996CrossRefGoogle Scholar
  15. 15.
    Thorlacius S, Thorgilsson B, Björnsson J, et al: TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur J Cancer 31A:1856–1861, 1995PubMedCrossRefGoogle Scholar
  16. 16.
    Zhang GJ, Kimijima I, Abe R, Watanabe T, et al: Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res 18: 1989–1998, 1998PubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2003

Authors and Affiliations

  • Esin Cengiz-Boduroglu
    • 1
  • Çigdem Irkkan
    • 1
  • Gülay Bilir
    • 1
  1. 1.Department of PathologyAnkara Oncology HospitalAnkaraTurkey

Personalised recommendations